FDAAA Impact Analysis (Year 5): The REMS Paradox
This article was originally published in RPM Report
FDA is approving new molecules at the fastest rate of the REMS era, while actually imposing REMS obligations less frequently than ever. That is good news for sponsors—but it doesn’t make a lot of sense if the REMS are working as intended. After five years, the role of REMS is still very much a work in progress.
You may also be interested in...
FDA’s use of REMS continues to fall to almost undetectable levels, with the agency using the safety tools just a handful of times in the sixth full year of the program. REMS are now very much the exception and not the rule for new products – but still a very important exception.
FDA’s John Jenkins disputes accusations that the pharmaceutical industry does not take post-marketing studies seriously and that the agency is lax on enforcement. According to updated data from FDA, Phase IV studies are being completed in a timely manner, Jenkins argues – and when they aren’t, the agency is taking action.
Flawed clinical trial overcomes meta-analysis safety signal as mortality data from the re-adjudicated RECORD trial persuades the rosiglitazone advisory committee that the product’s risk management program can be relaxed.